

**AACR Virtual Special Conference  
Ovarian Cancer**  
September 14-15, 2021

**September 14, 2021**

**Plenary Session 1: Epidemiology and Cancer Prevention**

*Session Chair: Elizabeth M. Swisher, University of Washington, Seattle, Washington*

Session Introduction

**Opportunistic salpingectomy: one decade later**

Jessica N. McAlpine, University of British Columbia, Vancouver, BC, Canada

**Ovarian cancer detection and risk assessment using high fidelity sequencing**

Rosana Risques, University of Washington, Seattle, WA

**PALB2, ovarian cancer gene?**

Barbara Norquist, University of Washington, Seattle, WA

**Endometriosis and ovarian cancer risk**

Holly Harris, Fred Hutchinson Cancer Center, Seattle, WA

Panel Discussion

**Plenary Session 2: Ovarian Cancer Genetics, Epigenetics, and Evolution**

*Session Chair: Benjamin G. Neel, NYU Langone Health Perlmutter Cancer Center, New York, New York*

Session Introduction

**Longitudinal, multi-region assessment of tumor evolution in patients with high-grade serous ovarian cancer**

Sampsa Hautaniemi, University of Helsinki, Helsinki, Finland

**Rewiring of transcriptional circuits during high-grade serous ovarian cancer development**

Kate Lawrenson, Cedars-Sinai Medical Center, Los Angeles, CA

**Genomic and immunological features of high-grade serous ovarian cancer in long-term survivors**

Dale W. Garsed, Peter MacCallum Cancer Centre, Melbourne, Australia

Panel Discussion

**September 15, 2021**

**Plenary Session 3: DNA Damage and Replication Stress**

*Session Chair: Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois*

Session Introduction

**Overcoming PARP inhibitor resistance**

Alan D'Andrea, Dana-Farber Cancer Institute, Boston, MA

**USP1-trapping lesions as a source of DNA replication stress and genomic instability**

Tony Huang, NYU Langone Health Perlmutter Cancer Center, New York, NY

**The role of BRCA1 mutations and therapy resistance**

Neil Johnson, Fox Chase Cancer Center, Philadelphia, PA

**The success and challenges of introducing PARP inhibitors into the therapy of ovarian cancer**

Jonathan A. Ledermann, UCL Cancer Institute at University College London, London, United Kingdom

Panel Discussion

**Plenary Session 4: Immunology and Tumor Microenvironment**

*Session Chair: Frances R. Balkwill, Barts Cancer Institute, Queen Mary University of London, London, England*

Session Introduction

**Single-cell spatial proteomic profiling of the tumor microenvironment for biomarker discovery in ovarian cancer**

Anniina Färkkilä, University of Helsinki, Helsinki, Finland

**Engineering adoptive T cell therapy to overcome immune suppression in ovarian cancer**

Kristin G. Anderson, Fred Hutchinson Cancer Center, Seattle, WA

**Mechanisms of tumor immunogenicity and anti-tumor immunity in ovarian cancer**

Denarda Dangaj, Ludwig Institute for Cancer Research UNIL CHUV, Lausanne, Switzerland

**Mutational processes as determinants of immunophenotypes in ovarian cancer**

Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York